Company News

Lupin has allotted 40988 equity shares under ESOP on 25 September 2017. With this allotment, the paid up capital of the Company has increased to Rs 90.37 crore consisting of 45,18,38,126 equity shares of Rs 2 each.

Lupin announced that it has received final approval for its Metronidazole Tablets USP, 250 mg and 500 mg from the USFDA to market a generic version of G D Searle LLC's Flagyl Tablets, 250 mg and 500 mg.

The announcement was made during market hours today, 11 September 2017.

Meanwhile, the S&P BSE Sensex was up 234.70 points or 0.74% at 31,922.22.

On the BSE, 2.71 lakh shares were traded on the counter so far as against the average daily volumes of 1.78 lakh shares in the past one quarter. The stock had hit a high of Rs 982.65 and a low of Rs 969 so far during the day. The stock had hit a 52-week high of Rs 1,590 on 9 September 2016 and a 52-week low of Rs 920 on 21 August 2017.

The stock had outperformed the market over the past one month till 8 September 2017, sliding 0.65% compared with the Sensex's 1.02% fall. The stock had, however, underperformed the market over the past one quarter, sliding 17.16% as against the Sensex's 1.52% rise. The scrip had also underperformed the market over the past one year, declining 38.7% as against the Sensex's 9.1% rise.

The large-cap company has equity capital of Rs 90.36 crore. Face value per share is Rs 2.

Lupin said it has received final approval for its Doxycycline Hyclate Tablet USP, 100 mg from the United States Food and Drug Administration (FDA) to market a generic version of Pfizer Inc.'s Vibra-Tabs, 100 mg.

Lupin's Doxycycline Hyclate Tablet USP, 100 mg is the AB rated generic equivalent of Pfizer Inc.'s Vibra-Tabs, 100 mg. It is indicated in the treatment of infections caused by various microorganisms and as an adjunctive therapy in severe acne.

Doxycycline Hyclate Tablet USP, 100 mg had US sales of $149.9 million (IMS MAT June 2017).